News

11 Most Undervalued US Stocks According To Analysts
He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...
The Pharma Letter18h
Salanersen shines in early spinal muscular atrophy research
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...
Investor's Business Daily on MSN20h
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $213.00. The company’s shares cl ...
pharmaphorum23h
Could a vaccine adjuvant be protective against dementia?
It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...
Wells Fargo Remains a Hold on Biogen (BIIB)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $140.00. The company’s shares ...